Proton Therapy in the Management of Localized Prostate Cancer in Young Men Authors: Miscia Fortna, Nancy P Mendenhall, Daniel Lichlyter, Samuel Jean-Baptiste, William M Mendenhall, R Charles Nichols, Curtis M Bryant Published: 2026 ABSTRACT AbstractPurposeWe present long-term outcomes of men young aged 50 years or younger treated for localized prostatic adenocarcinoma with image-guided proton therapy (PT).Patient and MethodsWe identified 85 patients with localized prostate cancer treated with PT between 2006 and 2017 at our institution. Patients were treated with double scattered PT to a median dose of 78 GyRBE (range, 78-82) delivered at 2 GyRBE/fraction. Nine (11%) received androgen deprivation therapy for a median of 6 months (range, 6-7). Biochemical control was defined by the Phoenix Definition. Physician-reported toxicity assessed according to CTCAE v5.0. Patient reported outcomes were assessed with the International Prostate Symptom Score and Expanded Prostate Index Composite (EPIC). Freedom from Biochemical Failure (FFBF) was tabulated with Kaplan-Meier method.ResultsMedian follow-up was 12.3 years (range, 1.58-17.4). FFBF rates by risk category at 10 years were very low 100%, low 100%, favorable intermediate 92%, unfavorable intermediate 93%, and high 100%. Three developed disease progression at 10 years. All had biochemical progression, and one recurred with regional nodal metastases. Grade 2+ gastrointestinal toxicity occurred in 2 (2.4%), and grade 3+ urologic toxicity occurred in 2 (2.4%). Median EPIC summary scores for urinary and bowel outcomes were 97.1 and 98.1 at baseline and 95.8 and 96.4 at 10 years respectively. Median EPIC sexual summary score was 82.7 at baseline and 69.2 at 10 years respectively. Two patients developed a second cancer, and both were out-of-field. One occurred in the submandibular gland 7 years after treatment, and the other in the pancreas 10 years after treatment.ConclusionPT provides excellent tumor control for patients 50 years or younger with localized prostate cancer and has a low risk for high-grade toxicities. No in-field secondary cancers were observed. Findings from this relatively small population should be confirmed in a larger study population.Keywords: Proton therapy, Prostate cancer, Research outcomes Introduction Prostate cancer is the most common cancer in the US, with about 313 780 expected new cases in 2025.1 Over time the average yearly incidence of prostate cancer among younger patients has been significantly increasing, outpacing the incidence increase of the older population.2 Currently in the US, the majority of younger patients are treated with radical prostatectomy, and surveys have shown that the main reason for this preference is due to perceived notions of better tumor control over external beam radiation therapy among urologists.3 Although the American Society for Radiation Oncology and the American Urological Association support that radical prostatectomy and external beam radiation therapy have negligible differences in tumor outcome,4, 5 the majority of patients in clinical trials supporting this statement were older than 50 years. The efficacy and safety of radiation therapy still needs to further be studied among younger cohorts. Among young patients, proton therapy may be a good option as it minimizes excess radiation therapy delivered to the rectum, bladder, and the remainder of the pelvis. While there are several published studies documenting the long-term prostate cancer outcomes using proton therapy,6, 7 the experience focusing on younger patients remains limited. This study seeks to build upon the findings of the previous successive proton therapy outcome reports,6, 7 with a specific focus on younger patients. Patients and methods Patients We utilized an Institutional Review Board-approved prospective longitudinal clinical outcome study (IRB202001258) to identify the medical records of 3089 patients with biopsy-proven localized prostate cancer treated consecutively with proton therapy at the University of Florida Health Proton Therapy Institute from 2006 and 2017 on a prospective outcome tracking protocol. Patients from the set of 3089 were excluded from this study if they were older than 50 years of age at the time of radiation treatment. In addition, patients with the following were excluded from this study: 1) presence of pretreatment distant/nodal metastases, 2) prior radical prostatectomy or prostate radiation therapy, 3) use of non-proton radiation therapy, 4) concurrent chemotherapy, and/or 5) hypofractionated radiation therapy. After these exclusions, a total of 85 patients were included in this study. These patients had biochemical, clinical, and patient-reported health-related quality of life (HRQoL) data collected prospectively at regular intervals. Treatment simulation, planning, and delivery The treatment planning procedures have also been previously described.7 The clinical target volume (CTV) for low-risk patients included only the prostate as visualized on fused MRI and CT images; the CTV in intermediate-risk and high-risk patients also included the proximal 2 cm of seminal vesicles. Elective nodal RT was not delivered for any risk category. The CTV was expanded by 5 mm axially and 8 mm in the superior and inferior axes to create a planning target volume (PTV); in 2008, the parameters for PTV expansion were reduced to 4 mm axially and 6 mm in the superior and inferior axes as the result of an internal intrafraction motion analysis. Lateral or oblique fields were used with PT. The treatment planning guidelines included goals for both target coverage and dose constraints for organs at risks, including the bladder, bladder wall, rectum, rectal wall, and femoral heads. For target coverage, 95% of the PTV received 100% of the prescribed dose, and 100% of the PTV received at least 95% of the prescribed dose. Minor adjustments were allowed when dose constraint goals to the organs at risks could not be met. Median PT dose was 78 GyRBE (range, 78-82) delivered at 2 GyRBE/fraction. Androgen deprivation therapy (ADT) was recommended for patients with unfavorable intermediate risk and high-risk prostate cancer, but its receipt was variable and depended on patient decision-making. In total, 9 patients received ADT for a median of 6 months (range, 6-7). The patient and treatment characteristics for the patient cohort are listed in Table 1. Table 1Patient characteristics (N = 85).CharacteristicsNumber of patients (%) or other valueMedian follow-up (range)12.33 y (1.58-17.42)Median age (range)49 y (37-50.9)Tumor stage T1T2T361 (72)24 (28)0 (0)Gleason score ≤ 63+4=74+3=78–1050 (59)22 (26)9 (10)4 (5)PSA < 1010–20>2076 (90)8 (9)1 (1)NCCN Risk Very lowLowFavorable IntermediateUnfavorable IntermediateHighVery high23 (31)15 (18)25 (29)14 (16)5 (6)0 (0)Proton Therapy Dosea 78 GyRBE80–82 GyRBE78 (92)7 (8)ADT YesNo9 (11)76 (89)Abbreviations: PSA, prostate-specific antigen; NCCN, National Comprehensive Cancer Network; Gy, Gray; RBE, relative biological equivalent; ADT, androgen deprivation therapyaAll at 2 GyRBE/fraction. Patient characteristics (N = 85). Abbreviations: PSA, prostate-specific antigen; NCCN, National Comprehensive Cancer Network; Gy, Gray; RBE, relative biological equivalent; ADT, androgen deprivation therapy All at 2 GyRBE/fraction. Follow-ups, physical examinations, medical history review, and prostate-specific antigen (PSA) tests were systematically performed at 3-month intervals for the first 3-year post-treatment and then semiannually. Biochemical failure was defined according to the Phoenix definition of PSA nadir + 2 ng/mL.8 Clinical failure (local, regional, or distant) was based on clinical, histologic, and/or radiographic evidence of disease recurrence. For patients experiencing biochemical failure, further evaluations with nuclear medicine bone scans, pelvic magnetic resonance imaging (MRIs), and/or positron emission tomography (PET)/computed tomography scans were commonly performed. Prostate biopsies were not performed in the event of biochemical failure unless the results of a positron emission tomography/computed tomography scan, pelvic MRI, and/or digital rectal examination suggested possible local disease progression. Although toxicities were often assessed using older versions of the Common Terminology Criteria for Adverse Events (CTCAE v3.0, 4.0) scale, all instances of toxicities documented in prior years were retrospectively reclassified as CTCAE v5.0 events. The Expanded Prostate Cancer Index Composite (EPIC) score was used to document HRQoL outcomes at baseline and at 6-month intervals after proton therapy. The EPIC indices measured include urinary summary, bowel summary, and sexual summary scores. International Prostate Symptom Scores (IPSS) were also recorded at the same time points and are reported to document patient-reported urinary function over time. Statistical analysis Statistical analyses were performed with SAS and JMP software (SAS Institute, Cary, NC). The Kaplan-Meier product-limit method was used for the evaluation of the freedom from biochemical progression (FFBP) as well as from other specific disease progression instances like local recurrence, distant metastasis, and nodal/regional metastasis. A P value of <.05 was considered statistically significant. The EPIC scores for HRQoL outcomes were evaluated based on clinically significant outcome thresholds established by the minimally important difference values of Skolarus et al, 2015.9 Results Disease control The median follow-up time for the study was 12.3 years (range, 1.58-17.4). The overall biochemical control was 96% of the patient population at 10 years. As noted in Table 2, by risk category, 10 year freedom from biochemical failure was as follows: very low (VLR) was 100%, low (LR) was 100%, favorable intermediate (FIR) was 92%, unfavorable intermediate (UIR) was 93%, and high (HR) was 100%. The median time to biochemical failure was 6.92 years (range, 1.25-8.33). The overall median PSA nadir was 0.3 ng/mL (range, 0-2.35). By risk category: VLR was 0.49 ng/mL (range, 0.02-1.90), LR was 0.30 ng/mL (range, 0.01-0.90), FIR was 0.33 ng/mL (range, 0.00-2.35), UIR was 0.19 ng/mL (range, 0.10-1.93), and HR was 0.19 ng/mL (range, 0.08-1.50). The overall median time to nadir was 5.58 years (range, 0.33-17.25). By risk category: VLR was 5.54 years (range, 1.42-16.17), LR was 5.75 years (range, 0.50-13.5), FIR was 5.75 years (range, 0.50-17.25), UIR was 5.46 years (range, 0.33-15.58), and HR was 0.67 years (range, 0.42-9.25). For patients who did not receive ADT (n = 74), median PSA nadir was 0.3 ng/mL (0.01-2.35) and occurred at a median of 5.75 years (range 0.25-17 years). Median PSA nadir was <0.1 ng/mL (0.02-1.93) and occurred at a median of 0.5 year (range 0.4-12 years) for patients who did receive ADT (n = 9). Table 2Disease progression rates.Progression rateValue (%) [Range]FFBF by Risk at 10-y Very low riskLow riskFavorable intermediate riskUnfavorable intermediate riskHigh risk1001009293100Overall FFBF 5-y10-y98.8 [92.0-99.8]95.4 [86.7-98.6]Distant metastasis free survival 5-y10-yN/AaN/AaRegional nodal metastasis free survival 5-y10-y98.8 [92.0-99.8]98.8 [92.0-99.8]Local recurrence free survival 5-y10-yN/AaN/AaAbbreviations: FFBR, freedom from biochemical failure.aRefers to the absence of any incident. Disease progression rates. Abbreviations: FFBR, freedom from biochemical failure. Refers to the absence of any incident. Survival percentages and tumor control endpoints are displayed at 5 and 10 years in Table 2. Only 3 patients (3.5%) had biochemical progression. The median time from the end of treatment to biochemical failure was 6.92 years (range, 1.25-8.33). One patient (1.2%) experienced a clinical failure and had a regional nodal metastasis at 1.25 years post-treatment. There were no instances of distant metastasis or local recurrence. At 10 years, 2 patients died of intercurrent disease. Over the course of the study, there were 2 instances of a second cancer. The first was an adenocarcinoma of the submandibular gland that occurred in a patient who was 7 years post treatment. The second was a pancreatic neuroendocrine tumor that occurred in a second patient 10 years after proton therapy. Neither of these tumors were in-field second cancers. Toxicity At 10 years, 2 patients (2.4%) experienced late CTCAE v5.0 grade (G)3+ genitourinary (GU) toxicity. One patient developed G3 urinary obstruction 2 years post-treatment. The patient underwent transurethral resection of the prostate to relieve his urinary obstruction. This patient had a pretreatment IPSS score of 16 and a prostate volume of 69 cc. The other patient developed G3 urinary obstruction and underwent transurethral microwave therapy. This patient later experienced G3 urinary incontinence and G3 hematuria toxicities at 6.83 years post-treatment. He was treated with an external catheter and hyperbaric oxygen treatments. The patient eventually required a nonemergent cystoprostatectomy and urinary diversion due to recurrent episodes of obstruction. This patient had a pretreatment IPSS score of 9 and a prostate volume of 11. At 10 years, 1 patient (1.2%) experienced a late G2+ gastrointestinal (GI) toxicity occurring 4.75 years after proton therapy. The patient experienced rectal bleeding that led to a colonoscopy. He was diagnosed with radiation proctitis, which was treated successfully with argon plasma coagulation. Patient reported outcomes The median patient reported HRQoL outcomes are displayed at baseline, 5 and 10 years in Figure 1. For the EPIC urinary summary score (Figure 1A), bowel summary score (Figure 1B) and IPSS score (Figure 1D), no clinically significant decline was noted. For the EPIC sexual summary score (Figure 1C), the median value at baseline was 82.7 (range, 37.2-100). At 5 years, the median decreased to 65.4 (range, 0-96.2) and at 10 years, the median was 69.2 (range, 23.7-89.6). These were clinically significant declines in EPIC sexual scores. Health-related quality of life median scores over time. (A) Urinary summary score, (B) Bowel summary score, (C) Sexual summary score, and (D) IPSS. *Denotes clinically significant difference. Abbreviations: IPSS, Internation Prostate Symptom Score. Discussion Proton therapy has demonstrated excellent tumor control, low rates of high-grade toxicity, and patient outcomes among younger patients treated for prostate cancer. To our knowledge, our study has the longest median follow-up time of any prostate cancer outcome study in younger men. In general, physician-reported toxicity rates were acceptably low and patient-reported outcomes did not show a significant decline after proton therapy, with the only exception being sexual summary. In addition, there were only 2 instances of second malignancies after treatment, and they were out-of-field and unlikely to be related to proton therapy. The FFBP rates at 5 and 10 years were 98.80% and 95.40%, respectively. As displayed in Table 3, our results are similar to other outcome studies featuring patients with localized prostate cancer treated with proton therapy and having extensive follow-up.10, 11, 12, 13, 14 Among studies featuring only young men treated for prostate cancer, it appears that expected rates of biochemical control are excellent after radical prostatectomy and brachytherapy as well.12, 15, 16, 17 Still, our study is unique as it shows evidence that proton therapy may pose a low risk for late G2+ GI and G3+ GU toxicity in this population, whereas detailed toxicity data is lacking among studies featuring other modalities. Table 3Literature review of prostate cancer outcomes studies.Reference (y)Overall pts & Agea (y)Modality (y)Dose/FractionationMedian F/U (y)FFBP (%)Toxicity (%)Late Grade 2 GILate Grade 3+ GILate Grade 3+ GUTreatment Outcomes for Young MenFortna et al (Current series)85 ≤50Proton therapy2006-201778-82 GyRBE / 39-4112.335-y: 98.810-y: 95.45-y: 1.2a10-y: 1.2a5-y: 0b10-y: 0b5-y:2.4b10-y: 2.4bZeighami et al (2025)1726≤55Radical prostatectomy2011-2019--6.755 y: 96------Burri et al (2010)12378≤60Brachytherapy +/- EBRT1990-2003BED > 150 Gy in 95% of pts55-y: 958-y: 92Rectal bleeding grade unk: 32Urinary retention grade unk: 7----Winoker et al (2019)15423≤60Brachytherapy +/- EBRTMedian BED 205.8 Gy9.910-y: 9915-y: 880.5----Milonas et al (2017)16277≤55Radical prostatectomy2001-2015--45-y: 778-y: 88-------Treatment Outcomes After Proton Therapy for all MenHenderson et al (2026)1358266Proton therapy70-72.5 GyRBE / 28-2910.210-y:LR: 92IR: 85HR: 88--10-y: 1.4b10-y: 2.7bBryant et al (2021)7127266Proton therapy72-82 GyRBE / 40-4110.210-y: 86.32--7-y: 1.3b 10-y: 1.3b7-y: 6.2b10-y: 6.2bSosa et al (2023)14277266Proton therapy76-78 GyRBE / 38-397.5-y: 96.0510-y: 91.291.01c0.87cMendenhall et al (2014)621164Proton therapy72-82 GyRBE/40-415.25-y:LR: 99UR: 99HR: 76--5-y: 0.5d5-y: 1.0d--Indicates not reportedAbbreviations: Y(s), year(s); FFBP, freedom from biochemical progression; GI, gastrointestinal; GU, genitourinary; Gy, Gray; RBE, relative biological equivalent; EBRT, external beam radiation therapy; unk, unknown; BED, biological effective dose; LR, low risk; IR, intermediate risk; HR, high risk; CTCAE, Common Terminology Criteria for Adverse EventsaAge limit of young men; median age after PT for all men.bCTCAE v5.0.cRTOG.dCTCAE v4.0. Literature review of prostate cancer outcomes studies. --Indicates not reported Abbreviations: Y(s), year(s); FFBP, freedom from biochemical progression; GI, gastrointestinal; GU, genitourinary; Gy, Gray; RBE, relative biological equivalent; EBRT, external beam radiation therapy; unk, unknown; BED, biological effective dose; LR, low risk; IR, intermediate risk; HR, high risk; CTCAE, Common Terminology Criteria for Adverse Events Age limit of young men; median age after PT for all men. CTCAE v5.0. RTOG. CTCAE v4.0. Our study has several strengths and weaknesses. Among its strengths is the extensive follow-up time, which surpassed a median of 12 years. It is also one of the only studies focusing on the efficacy and safety of radiation therapy in the management of prostate cancer among young men. Our study is limited by its small population size and the potential selection bias existing among patients who sought out proton therapy at University of Florida Health Proton Therapy Institute. These patients may be fundamentally different than the majority of prostate cancer patients in unknown ways. Completing a larger multi-institutional trial featuring young men with localized prostate cancer would help to verify the findings of this study. In addition, the form of proton therapy included in this study was passive-scattering proton therapy. It would be of value to evaluate these outcomes in a study featuring using the pencil-beam scanning proton therapy, which is a more advanced and more conformal form of proton therapy delivery. Conclusion Proton therapy is an effective in the management of localized prostate cancer in patients 50 years or younger. The risk for high-grade toxicity is low and tumor control rates are excellent. Due to the small number of patients, these findings need to be confirmed in larger study population. Ethics The study protocol was approved by the University of Florida Institutional Review Board (IRB202001258). All participants provided informed consent to participate in this study. Funding This study received no funding. Data availability The authors agree to share anonymized data upon reasonable request by researchers. CRediT authorship contribution statement Miscia Fortna: Conceptualization, Data Curation, Formal Analysis, Methodology, Methodology, Software, Writing – Original Draft, Writing – Review and Editing. Nancy P. Mendenhall: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Writing – Review and Editing. Daniel Lichlyter: Data Curation, Methodology, Software, Writing – Review and Editing. Samuel Jean-Baptiste: Investigation, Resources, Validation, Writing – Review and Editing. William M. Mendenhall: Investigation, Resources, Validation, Writing – Review and Editing. R. Charles Nichols: Investigation, Resources, Validation, Writing – Review and Editing. Curtis M. Bryant: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Writing – Review and Editing. Declaration of Conflicts of Interest The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: NPM is the Editor-in-Chief of IJPT, WMM is the Advisory Editor for IJPT, and CMB is an Associate Editor for IJPT. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. References Associated Data Data Availability Statement The authors agree to share anonymized data upon reasonable request by researchers.